Kanada - Inggeris - Health Canada

viiv healthcare ulc - dolutegravir (dolutegravir sodium) - tablet for suspension - 5mg - dolutegravir (dolutegravir sodium) 5mg - miscellaneous antiretrovirals*

Kanada - Inggeris - Health Canada

viiv healthcare ulc - dolutegravir (dolutegravir sodium); abacavir (abacavir sulfate); lamivudine - tablet - 50mg; 600mg; 300mg - dolutegravir (dolutegravir sodium) 50mg; abacavir (abacavir sulfate) 600mg; lamivudine 300mg - hiv integrase inhibitors

Tanzania - Inggeris - Tanzania Medicinces & Medical Devices Authority

macleods pharmaceuticals limited, india - dolutegravir sodium - film coated tablet - 10

Singapura - Inggeris - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - dolutegravir sodium 52.6mg eqv dolutegravir - tablet, film coated - 50mg - dolutegravir sodium 52.6mg eqv dolutegravir 50mg

Singapura - Inggeris - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - dolutegravir sodium 10.5mg equ dolutegravir - tablet, film coated - dolutegravir sodium 10.5mg equ dolutegravir 10mg

Singapura - Inggeris - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - dolutegravir sodium 26.3mg eqv dolutegravir - tablet, film coated - dolutegravir sodium 26.3mg eqv dolutegravir 25mg

Singapura - Inggeris - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - abacavir sulfate 702.0mg eqv abacavir; dolutegravir sodium 52.6mg eqv dolutegravir; lamivudine - tablet, film coated - abacavir sulfate 702.0mg eqv abacavir 600 mg; dolutegravir sodium 52.6mg eqv dolutegravir 50 mg; lamivudine 300 mg

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - dolutegravir sodium 52.6mg equivalent to dolutegravir 50mg;  ;  ; lamivudine 300mg;   - film coated tablet - active: dolutegravir sodium 52.6mg equivalent to dolutegravir 50mg     lamivudine 300mg   excipient: magnesium stearate mannitol microcrystalline cellulose opadry white oy-s-28876 povidone purified water sodium starch glycolate sodium stearyl fumarate - indicated for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents from 12 years of age weighing at least 40kg, who have no known or suspected resistance to either antiretroviral component.